Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 14/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23138402 | 0.91 | ACHE (0.46) | ACHETSHRALDH1A1 | |
| SCHEMBL22381321 | 0.87 | ACHE (0.55) | ACHE | |
| SCHEMBL30354527 | 0.85 | ACHE (0.60) | ACHE | |
| SCHEMBL25808995 | 0.83 | TSHR (0.43) | ACHETSHRALDH1A1 | |
| SCHEMBL23607511 | 0.80 | ACHE (0.66) | ACHE | |
| SCHEMBL16013082 | 0.80 | ACHE (0.51) | ACHE | |
| SCHEMBL30080469 | 0.78 | ACHE (0.51) | ACHE | |
| SCHEMBL19513091 | 0.78 | ACHE (0.58) | ACHE | |
| SCHEMBL16166336 | 0.77 | ACHE (0.57) | ACHE | |
| SCHEMBL25808981 | 0.77 | DGKA (0.44) | TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787906-B2 | Biodegradable drug-polymer conjugate | POLYACTIVA PTY LTD (AU) | 2023-10-17 | — | — | US | disclosed |
| US-11696955-B2 | Drug-polymer conjugate | POLYACTIVA PTY LTD (AU) | 2023-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11696955-B2 | Drug-polymer conjugate | PTGDR, PTGDR2, PTGER3 | ACHE 3335/4885TSHR 517/4885ALDH1A1 868/4885 |
| US-11787906-B2 | Biodegradable drug-polymer conjugate | ADRB3, PTGER3, CHRM3 | ACHE 351/4885TSHR 609/4885ALDH1A1 907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.